One project, six partners developing effective treatment for Leishmaniasis in East Africa.
Research and development (R&D) project, AfriCoLeish, is supported by the European Union Seventh Framework Programme (EU FP7) through a grant of €3 million. The project will run for three years and aims to test new treatments for kala-azar (visceral leishmaniasis, or VL) and co-infection of the disease with HIV in Ethiopia and Sudan.
The AfriCoLeish project, ‘Care Package for Treatment and Control of Visceral Leishmaniasis in East Africa’, aims to develop and deliver a shorter combination treatment for kala-azar patients that is equally as safe and effective as the current WHO-recommended first-line treatment for the disease (sodium stibogluconate and paromomycin, SSG&PM) in East Africa. The project aims to determine appropriate treatment strategies for kala-azar in patients that are also HIV positive, in order to treat and also prevent repetitive relapses that are common in co-infected patients.
Through a randomized clinical trial in Eastern Africa, the project will, for the first time, provide conclusive evidence-based data on the WHO recommendation to treat kala-azar/HIV co-infected patients using AmBisome 40 mg/kg total dose, and on the locally used regimen of AmBisome 30mg/kg in combination with Miltefosine that is used by MSF in Ethiopia. To do this, AfriCoLeish bring together six partners from Europe and East Africa with vast experience in R&D and treatment of HIV and kala-azar, namely the Drugs for Neglected Diseases initiative (DNDi); the Institute of Tropical Medicine in Antwerp (ITM-Antwerp); the London School of Hygiene and Tropical Medicine (LSHTM); Médecins Sans Frontieres (MSF, The Netherlands); the Institute of Endemic Diseases, University of Khartoum (IEND), Sudan; and the University of Gondar (UoG), Ethiopia.
The AfriCoLeish project addresses the FP7 Health call objectives, which are: to develop and deliver a package of care for VL patients in East Africa through safe and cost-effective treatments, therefore improving current case management and contributing to disease control in the region . AfriCoLeish aims to develop and deliver a package of care for VL patients in East Africa through safe and cost effective treatments, therefore improving current case management and contributing to disease control in the region.